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The gastrointestinal microbiota plays a critical role in nutritional, metabolic, and immune functions in infants and young children
and has implications for future lung health status. Understanding the role of intestinal dysbiosis in chronic lung disease
progression will provide opportunities to design early interventions to improve the course of the disease. Gut microbiota is
established within the ﬁrst 1 to 3 years of life and remains relatively stable throughout the life span. In this review, we report
the recent development in research in gut-lung axis, with focus on the eﬀects of targeting microbiota of infants and children at
risk of or with progressive lung diseases. The basic concept is to exploit this approach in critical window to achieve the best
results in the control of future health.
1. Introduction
Clinical research in the last decades focused on host-microbe
crosstalk especially at intestinal level raising the hypothesis
that the gut microbiota is one of the key factors that deter-
mine host health. The immune and metabolic functions are
inﬂuenced by the colonization of intestine by friendly bacte-
ria [1] and a growing number of diseases derive from the gut
microbiota composition. The change in microbiota structure
often starts in the early life in children with or at risk of
chronic diseases, such as cystic ﬁbrosis [2, 3].
The microbiome is established within the ﬁrst 1 to 3 years
of life and remains relatively stable throughout the life span
[4]. The neonatal period is a critical window for immune
programming that aﬀects the global health status for a life-
time, and the development of the gut microbiota may help
predicting speciﬁc disease risk and disease progression or
elimination of disease altogether [5].
In this review, we analyze the main factors and phases of
early microbial imprinting, gut-lung axis in the progression
of chronic lung diseases in children, and the manipulation
of early-life gut microbiota for modifying history of lung
diseases in children.
2. Factors Influencing Gut Microbiota
Composition in Early Infancy
Environmental factors together with genetics and immune
system activity inﬂuence microbial colonization pattern in
newborns Table 1. The concept that the fetus is sterile has
been reconsidered after detection of microbial traces in fetal
and maternal compartments [6, 7]. It is now believed that
there is a prenatal colonization with vertically transferred
microbial material.
The type of delivery inﬂuences the pattern of coloniza-
tion in infant gut. Vaginally delivered infants are colonized
with bacterial communities from the mother’s vaginal and
intestinal tract. Infants born to cesarean section lack such
exposure, leading to the ﬁrst establishment of bacteria
similar to the human skin microbiota [8]. In addition, the
intestinal colonization by Lactobacillus, Biﬁdobacteria, and
Bacteroides in infants born by cesarean section is delayed [9].
Hindawi
Journal of Immunology Research
Volume 2017, Article ID 8450496, 5 pages
https://doi.org/10.1155/2017/8450496
Infant feeding inﬂuences the gut microbial composition
with long-lasting eﬀects. Breastfeeding has been associated
with a variety of long-term beneﬁcial eﬀects including lower
incidence of obesity [10], diabetes [11], and allergies [12, 13].
Breast milk is the gold standard in infant nutrition, because
it is species speciﬁcally adapted to the infant nutritional
needs and functional to drive the development of the
immune system. In addition to nutritional support, breast
milk provides bioactive constituents that promote the
growth of a wide and dynamic array of microorganisms
[14]. Colostrum has higher microbial diversity than transi-
tional and mature milk, and factors inﬂuencing the microbial
community in breast milk also depend on the mother’s nutri-
tional status and the type of delivery.
An infant gut microbiota dominated by Biﬁdobacteria
has consistently been associated with host health. The pre-
dominance of Biﬁdobacteria in breastfed infant stools was
ﬁrstly found over 100 years ago, suggesting that breast milk
contains speciﬁc molecules that stimulate the growth of these
bacteria, deﬁned as biﬁdus factors [15]. Today, compelling
evidence show that prebiotics in breastmilk promote the
growth of Biﬁdobacteria. The latter dominate the microbiota
of breastfed infants, whereas formula-fed infants had higher
proportions of Bacteroides and members of the Clostridium
coccoides and Lactobacillus groups [16]. In addition, breast-
feeding modulates innate immune response [17].
Antibiotics have a major impact on gut microbiome com-
position particularly in young infants. In the latter, the gut
bacteria structure is very unstable, and the continuous and
repeated use of antibiotics, especially if the antibiotic used
is a broad-spectrum one, profoundly alters gut microbial
structure with major late clinical consequences. Recent
papers show that prenatal use of antibiotics is associated with
an increased risk of subsequent asthma [18].
Of course, antibiotics are often necessary for certain con-
ditions, but their use should be considered in the light of the
new data summarized in Table 2. Russell and colleagues
found that perinatal antibiotic use exerts highly selective
modiﬁcations on resident gut ﬂora, which in turn lead to very
speciﬁc alterations in susceptibility to TH2- or TH1-/TH17-
driven lung inﬂammatory disease [19]. A recent study found
that children lacking four bacteria types were more likely to
develop asthma, but the only signiﬁcant environmental fac-
tor among these children was receiving more antibiotics in
their ﬁrst year of life than children with lower asthma risk
[18]. Early infantile infections including common intestinal
infections do change intestinal microbial structure with
long-lasting eﬀects [20].
3. Gut-Lung Axis in the Progression of Chronic
Lung Diseases in Children
The gut and respiratory epithelia provide a physical barrier
against microbial penetration, and colonization with the nor-
mal microbiota generates resistance to pathogens. The role of
microbiota in lung homeostasis and immunity is supported
by the poor outcomes of germ-free mice that were exposed
to acute infections [21] and their susceptibility to allergic air-
way disease [22]. Dysbiosis in the gut has recently been
linked to alterations in immune responses and to disease
development in the lungs. In the last few years, chronic lung
diseases, such as asthma and cystic ﬁbrosis, have been inves-
tigated to evaluate the potential role of intestinal dysbiosis in
their development. Primarily, exacerbations of chronic gut
and lung diseases share key conceptual features with the dys-
regulation of intestinal microbial ecosystem.
Cystic ﬁbrosis (CF) is a disease in which recurrent and
chronic infection leads to a progressive decline of lung func-
tion and ultimately to death. In observational studies in
humans, CF has been associated with aberrant microbial col-
onization of the intestinal and the respiratory tracts. These
ﬁndings are the likely consequences of the loss of CF trans-
membrane conductance regulator (CFTR) function and the
resulting altered microenvironment [23]. Mutations in CFTR
fundamentally aﬀect the airway and intestinal microenviron-
ment and result in abnormal colonization pattern of micro-
organisms in patients with CF even in the absence of
antibiotic exposure [24]. More severe CFTR allelic variants
such as homozygous DF508 correlate with more signiﬁcant
alterations in gut microbiome pattern. Chronic gut inﬂam-
mation is seen in CF even in the absence of overt gastrointes-
tinal symptoms and is thought to be a driver of systemic
inﬂammation, a hallmark of the disease [25]. The association
between gut microbial colonization in early life and respira-
tory outcomes in patients with CF has been investigated,
and breastfeeding was associated with delayed exacerbations,
gut diversity, and prolonged periods of well-being and spe-
ciﬁc bacterial communities in the gut prior to respiratory
complications [26]. Bacteria in the respiratory tract in CF
originate from intestinal microbiota and are thought to con-
tribute to the dynamic interactions between the host and
microbial communities in CF [27].
Studies have demonstrated also a relationship between
poor nutrition and the development of bronchopulmonary
dysplasia in preterm infants who require prolonged supple-
mental oxygen therapy [28]. No data are available regarding
gut dysbiosis in this setting.
Children developing asthma have a reduced gut micro-
bial diversity in the ﬁrst year of life as compared to healthy
children [29]. In particular, delivery mode has been associ-
ated with wheezing and asthma until school age, mediated
by speciﬁc gut bacterial groups [30]. The presence of beneﬁ-
cial bacteria, such as Biﬁdobacterium longum, and a reduc-
tion in Bacteroides fragilis [31] in the gut have been
associated with a lower incidence of asthma. The relative
abundance of the bacterial genera Lachnospira, Veillonella,
Faecalibacterium, and Rothia seems signiﬁcantly decreased
in children at risk of asthma, with consequent reduced
Table 1: Main factors and phases of early microbial imprinting.
(1) Prenatal (colonization with vertically transferred microbial
material)
(2) Delivery (cesarean section versus natural)
(3) Feeding (human milk versus formula milk)
(4) Infections
(5) Antibiotics
(6) Intestinal environment (cystic ﬁbrosis, short gut, celiac disease)
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levels of fecal acetate and dysregulation of enterohepatic
metabolites [31].
4. Manipulation of Early-Life Gut Microbiota in
Lung Diseases in Children
Oral administration of probiotics and prebiotics or a combi-
nation of both (the so-called “synbiotic approach”) could
indirectly inﬂuence the composition of airway microbiota
through the release of bacterial products or metabolites that
reach the lung and promote the outgrowth of beneﬁcial bac-
teria or directly, via microaspiration of the probiotic strain
from the intestinal tract to the airways [32]. These mecha-
nisms may restore a health-promoting microbiota and have
a beneﬁcial eﬀect on the course of the disease. Moreover,
few probiotic strains have a role in modifying the course of
lung diseases. In animal studies, Lactobacilli have profound
immunoregulatory eﬀects on the lung, but the results of clin-
ical trials in humans have been highly variable. Strain diﬀer-
ences may in part explain the observed variability.
In humans, administration of Lactobacillus GG (LGG)
negatively inﬂuenced the incidence of ventilator-associated
pneumonia [33] and reduced respiratory infections in
healthy as well as hospitalized children [34].
Asthma is a major potential target for probiotics, due to
its frequency, related pathogenesis, and the lack of consis-
tently eﬀective preventive strategies. However, data on early
intestinemicrobial manipulation aremissing, because asthma
develops progressively until school age, and the long-term
follow-up of probiotic and prebiotic study is limited.
Manipulation of gut microbiota in CF by changing die-
tary content of indigestible carbohydrate and short-chain
fatty acids, namely, butyrate, may improve undernutrition
and play an anti-inﬂammatory eﬀect on animals [35]. Resto-
ration of gut microbiota by probiotics improves nutritional
status, energy intake, and respiratory function in cystic ﬁbro-
sis [35]. Three RCT concluded that probiotic administration
in particular LGG and Lactobacillus reuteri has been related
with a reduction of episodes of pulmonary exacerbations in
children with CF [36–38]. The ﬁrst evidence of the potential
beneﬁts of probiotic administration in CF came from a pro-
spective randomized placebo-controlled crossover trial per-
formed in two groups of patients with CF chronically
colonized by Pseudomonas aeruginosa. Nineteen children
were given LGG for 6 months followed by placebo (oral
rehydration solution) for the subsequent 6 months. In paral-
lel, 19 children were given the placebo during 6 months then
the probiotic for the same period of time. The patients on
LGG had a signiﬁcant reduction of intestinal inﬂammation
and of episodes of pulmonary exacerbations and hospitaliza-
tion rates, with a decrease in IgG, suggesting that there is a
relationship between intestinal and pulmonary inﬂamma-
tion. The intake of this probiotic was associated with a signif-
icant increase of the maximal forced expiratory volume in 1
second (FEV1) compared to the placebo as well as to a signif-
icant increase of body weight [36]. In another prospective
randomized, double-blind, placebo-controlled study, 61
patients with CF were randomly assigned to receive 1010
colony-forming units Lactobacillus reuteri per day or
placebo for 6 months. Pulmonary exacerbations and the
number of upper respiratory tract infections were signiﬁ-
cantly reduced in the treatment group compared with the
placebo group [39].
As for bronchopulmonary dysplasia, no studies on
humans have been conducted with pre- or probiotics. More-
over, in intermittent hypoxia induced in animal models, the
supplementation with probiotics may improve pulmonary
status, by acting on the speciﬁc matrix metalloproteinases
suggesting a beneﬁcial eﬀect on lung inﬂammation. In addi-
tion, prebiotic uses have been associated with arrested lung
vascular endothelial growth factor signaling highly involved
in lung microvascular development, suggesting preservation
of angiogenesis [40].
However, the eﬀects of probiotics are likely to be time-
dependent, indicating the need for comparative clinical trials
evaluating early-life microbiota modulation impact on lung
health status. In particular, future studies are required in
order to analyze how gut microbial composition in early life
inﬂuence lung disease occurrence and history, investigating
also the role of functional foods in preventing and/or modi-
fying lung health status in children.
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Table 2: Gut microbiota alterations induced by antibiotic use.
Antibiotics Gut microbiota alterations Study References
Ciproﬂoxacin
Decrease of the taxonomic richness, diversity,
and evenness of the community
Healthy adult humans [41, 42]
Amoxicillin
Cefoperazone
Long-lasting alterations in the gut microbial
community including a decrease in overall diversity
Young mice [43]
Ampicillin
Vancomycin
Metronidazole
Neomycin
Decrease of microbial diversity and colonization
with antibiotic-resistant microbes
Young mice [44]
Ceftriaxone Gut microbiota dysbiosis Adult mice [45]
3Journal of Immunology Research
References
[1] C. A. Kerr, D. M. Grice, C. D. Tran et al., “Early life events
inﬂuence whole-of-life metabolic health via gut microﬂora
and gut permeability,” Critical Reviews in Microbiology,
vol. 41, pp. 326–340, 2015.
[2] G. Reid, P. Brigidi, J. P. Burton et al., “Microbes central to
human reproduction,” American Journal of Reproductive
Immunology, vol. 73, pp. 1–11, 2015.
[3] S. Rautava, R. Luoto, S. Salminen, and E. Isolauri, “Microbial
contact during pregnancy, intestinal colonization and human
disease,” Nature Reviews. Gastroenterology & Hepatology,
vol. 9, pp. 565–576, 2012.
[4] T. Yatsunenko, F. E. Rey, M. J. Manary et al., “Human gut
microbiome viewed across age and geography,” Nature,
vol. 486, pp. 222–227, 2012.
[5] J. C. Mandan, “Neonatal gastrointestinal and respiratory
microbiome in cystic ﬁbrosis: potential interactions and impli-
cations for systemic health,” Clinical Therapeutics, vol. 38,
pp. 740–746, 2016.
[6] S. Rautava, M. C. Collado, S. Salminen, and E. Isolauri, “Pro-
biotics modulate host-microbe interaction in the placenta
and fetal gut: a randomized, double-blind, placebo-controlled
trial,” Neonatology, vol. 102, pp. 178–184, 2012.
[7] K. Aagaard, J. Ma, K. M. Antony, R. Ganu, J. Petrosino, and
J. Versalovic, “The placenta harbors a unique microbiome,”
Science Translational Medicine, vol. 6, pp. 237–265, 2014.
[8] M. G. Dominguez-Bello, E. K. Costello, M. Contreras et al.,
“Delivery mode shapes the acquisition and structure of the
initial microbiota across multiple body habitats in newborns,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 107, pp. 11971–11975, 2010.
[9] I. Adlerberth, E. Lindberg, N. Aberg et al., “Reduced entero-
bacterial and increased staphylococcal colonization of the
infantile bowel: an eﬀect of hygienic lifestyle?” Pediatric
Research, vol. 59, pp. 96–101, 2006.
[10] M. Kalliomäki, M. C. Collado, S. Salminen, and E. Isolauri,
“Early diﬀerences in fecal microbiota composition in children
may predict overweight,” The American Journal of Clinical
Nutrition, vol. 87, pp. 534–538, 2008.
[11] C. G. Owen, R. M. Martin, P. H. Whincup, G. D. Smith,
and D. G. Cook, “Does breastfeeding inﬂuence risk of type 2
diabetes in later life? A quantitative analysis of published evi-
dence,” The American Journal of Clinical Nutrition, vol. 84,
pp. 1043–1054, 2006.
[12] M. Gdalevich, D. Mimouni, M. David, and M. Mimouni,
“Breast-feeding and the onset of atopic dermatitis in child-
hood: a systematic review and meta-analysis of prospective
studies,” Journal of the American Academy of Dermatology,
vol. 45, pp. 520–527, 2001.
[13] B. E. Snijders, C. Thijs, P. C. Dagnelie et al., “Breast-feeding
duration and infant atopic manifestations, by maternal allergic
status, in the ﬁrst 2 years of life (KOALA study),” The Journal
of Pediatrics, vol. 151, pp. 347–351, 2001.
[14] R. Cabrera-Rubio, M. C. Collado, K. Laitinen, S. Salminen, E.
Isolauri, and A. Mira, “The human milk microbiome changes
over lactation and is shaped by maternal weight and mode of
delivery,” The American Journal of Clinical Nutrition, vol. 96,
pp. 544–551, 2012.
[15] E. Moro, “Morphologische und biologische Untersuchung
über die Darmbakterien des Säuglings,” Jahrbuch für Kinder,
vol. 61, pp. 687–734, 1905.
[16] M. Fallani, D. Young, and J. Scott, “Intestinal microbiota of
6-week-old infants across Europe: geographic inﬂuence
beyond delivery mode, breast-feeding, and antibiotics,”
Journal of Pediatric Gastroenterology and Nutrition,
vol. 51, pp. 77–84, 2010.
[17] M. E. Belderbos, M. L. Houben, G. M. Bleekvan et al., “Breast-
feeding modulates neonatal innate immune responses: a
prospective birth cohort study,” Pediatric Allergy Immunology,
vol. 1, pp. 208–222, 2010.
[18] M. C. Arrieta, L. T. Stiemsma, P. A. Dimitriu et al., “Early
infancy microbial and metabolic alterations aﬀect risk of
childhood asthma,” Science Translational Medicine, vol. 7,
p. 307, 2015.
[19] S. L. Russell, M. J. Gold, L. A. Reynolds et al., “Perinatal
antibiotic-induced shifts in gut microbiota have diﬀerential
eﬀects on inﬂammatory lung diseases,” The Journal of Allergy
and Clinical Immunology, vol. 1, pp. 100–109, 2015.
[20] S. M. Karst, “Identiﬁcation of a novel cellular target and a
co-factor for norovirus infection - B cells & commensal
bacteria,” Gut Microbes, vol. 4, pp. 266–271, 2015.
[21] C. T. Fagundes, F. A. Amarai, A. T. Vieira et al., “Transient
TLR activation restores inﬂammatory response and ability to
control pulmonary bacterial infection in germfree mice,”
Journal of Immunology, vol. 188, pp. 1411–1420, 2012.
[22] T. Olszak, D. An, S. Zeissig et al., “Microbial exposure during
early life has persistent eﬀects on natural killer T cell function,”
Science, vol. 336, pp. 489–493, 2012.
[23] E. F. McKone, S. S. Emerson, K. L. Edwards, and M. L. Aitken,
“Eﬀect of genotype on phenotype and mortality in cystic
ﬁbrosis: a retrospective cohort study,” Lancet, vol. 361,
pp. 1671–1676, 2003.
[24] M. J. Cox, M. Allgaier, B. Taylor et al., “Airway microbiota and
pathogen abundance in age-stratiﬁed cystic ﬁbrosis patients,”
PloS One, vol. 5, p. 11044, 2010.
[25] A. Munck, “Cystic ﬁbrosis: evidence for gut inﬂammation,”
The International Journal of Biochemistry & Cell Biology,
vol. 52, pp. 180–183, 2012.
[26] A. G. Hoen, J. Li, and L. A. Moulton, “Associations between
gut microbial colonization in early life and respiratory out-
comes in cystic ﬁbrosis,” The Journal of Pediatrics, vol. 67,
pp. 138–147, 2015.
[27] G. B. Rogers, M. P. Carroll, L. R. Hoﬀman, A.W.Walker, D. A.
Fine, and K. D. Bruce, “Comparing the microbiota of the cystic
ﬁbrosis lung and human gut,” Gut Microbes, vol. 1, pp. 85–93,
2010.
[28] M. A. Biniwale and R. A. Ehrenkranz, “The role of nutrition
in the prevention and management of bronchopulmonary
dysplasia,” Seminars in Perinatology, vol. 30, pp. 200–208,
2006.
[29] T. R. Amsson, H. E. Jakobsson, A. F. Andersson, B. Björkstén,
L. Engstrand, and M. C. Jenmalm, “Low gut microbiota
diversity in early infancy precedes asthma at school age,”
Clinical and Experimental Allergy, vol. 44, pp. 842–850, 2014.
[30] F. A. NimwegenVan, J. Pemders, E. E. Stobberingh et al.,
“Mode and place of delivery, gastrointestinal microbiota, and
their inﬂuence on asthma and atopy,” The Journal of Allergy
and Clinical Immunology, vol. 128, pp. 948–955, 2011.
[31] C. Vael, V. Nelen, S. L. Verhulst, H. Goossens, and K. N.
Desager, “Early intestinal Bacteroides fragilis colonisation
and development of asthma,” BMC Pulmonary Medicine,
vol. 8, p. 19, 2008.
4 Journal of Immunology Research
[32] P. Forsythe, “Probiotics and lung diseases,” Chest, vol. 139,
pp. 901–908, 2011.
[33] K. Hatakka, E. Savilahti, A. Ponka et al., “Eﬀect of long term
consumption of probiotic milk on infections in children
attending day care centres: double blind, randomised trial,”
BMJ, vol. 322, p. 1327, 2001.
[34] I. Hojsak, S. Abdovic, and H. Szajewska, “Lactobacillus GG in
the prevention of nosocomial gastrointestinal and respiratory
tract infections,” Pediatrics, vol. 125, pp. 1171–1177, 2010.
[35] L. Li and S. Somerset, “The clinical signiﬁcance of the gut
microbiota in cystic ﬁbrosis and the potential for dietary ther-
apies,” Clinical Nutrition, vol. 33, pp. 571–580, 2014.
[36] E. Bruzzese, V. Raia, M. I. Spagnuolo et al., “Eﬀect of Lactoba-
cillus GG supplementation on pulmonary exacerbations in
patients with cystic ﬁbrosis: a pilot study,” Clinical Nutrition,
vol. 26, pp. 322–328, 2007.
[37] B. Weiss, Y. Bujanover, Y. Yahav, D. Vilozni, E. Fireman, and
O. Efrati, “Probiotic supplementation aﬀects pulmonary
exacerbations in patients with cystic ﬁbrosis: a pilot study,”
Pediatric Pulmonology, vol. 45, pp. 536–540, 2010.
[38] G. NardoDi, S. Oliva, A. Menichella et al., “Lactobacillus
reuteri ATCC55730 in cystic ﬁbrosis,” Journal of Pediatric
Gastroenterology and Nutrition, vol. 58, pp. 81–86, 2010.
[39] A. Ananthan, H. Bakasubramanian, S. Rao, and S. Patole,
“Probiotic supplementation in children with cystic ﬁbrosis: a
systematic review,” European Journal of Pediatrics, vol. 175,
pp. 1255–1266, 2016.
[40] A. Ahmad, C. L. Cai, D. Kumar et al., “Beneﬁts of pre-, pro-
and syn-biotics for lung angiogenesis in malnutritional rats
exposed to intermittent hypoxia,” American Journal of
Translational Research, vol. 6, pp. 459–470, 2014.
[41] L. Dethlefsen, S. Huse, M. L. Sogin, and D. A. Relman, “The
pervasive eﬀects of an antibiotic on the human gut
microbiota, as revealed by deep 16S rRNA sequencing,” PLoS
Biology, vol. 6, no. 11, article e280, 2008.
[42] L. Dethlefsen and D. A. Relman, “Incomplete recovery and
individualized responses of the human distal gut microbiota
to repeated antibiotic perturbation,” Proceedings of the
National Academy of Sciences, vol. 108, Supplement 1,
pp. 4554–4561, 2010.
[43] D. A. Antonopoulos, S. M. Huse, H. G. Morrison, T. M.
Schmidt, M. L. Sogin, and V. B. Young, “Reproducible
community dynamics of the gastrointestinal microbiota
following antibiotic perturbation,” Infection and Immunity,
vol. 77, no. 6, pp. 2367–2375, 2009.
[44] C. Ubeda, Y. Taur, R. R. Jenq et al., “Vancomycin-resistant
Enterococcus domination of intestinal microbiota is enabled
by antibiotic treatment in mice and precedes bloodstream
invasion in humans,” Journal of Clinical Investigation,
vol. 120, no. 12, pp. 4332–4341, 2010.
[45] Y. Guo, X. Yang, Y. Qi et al., “Long-term use of ceftriaxone
sodium induced changes in gut microbiota and immune
system,” Scientiﬁc Reports, vol. 7, article 43035, 2017.
5Journal of Immunology Research
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
